Mentioned:
DMT is one of the most powerful psychedelic compounds in existence. And it might also be a breakthrough treatment for alcoholism.
What’s happening:
- atai Life Sciences (NASDAQ: ATAI) has announced positive clinical data from their portfolio company Beckley Psytech’s Phase II open label study of BPL-003 for Alcohol Use Disorder
By the numbers:
- 50% of the patients involved in the clinical trial were able to abstain from alcohol completely for 90 days following a single dose of BPL-003, which is an intranasal 5-MeO-DMT benzoate formulation
- The vast majority of patients were ready to be discharged just 2 hours after receiving a dose of BPL-003
Why it matters:
- atai Life Sciences is one of the most advanced psychedelic medicine companies in the world and also has landed some of the most notable investors of any publicly traded psychedelic drug development company, with notable backers that include Christian Angermayer, Mike Novogratz and Peter Thiel
Going deeper:
- Beckley Psytech is also advancing another Phase II clinical trial for BPL-003 which is focused on treatment resistant depression
The intrigue:
- Psychedelic medicines continue to gain meaningful traction with regulators, including the recent notable approval from the United States Food and Drug Administration for Johnson & Johnson’s (NYSE: JNJ) Spravato
